- Conditions
- Mesothelioma
- Interventions
- MEDI4736, Tremelimumab, no other name
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 4,239
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Gastrointestinal Graft vs Host Disease
- Interventions
- oral beclomethasone 17,21-dipropionate, Placebo
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Durham, North Carolina • Seattle, Washington
- Conditions
- Sleep Disturbance
- Interventions
- Sleep Supplement, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- Bonafide Health
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Harrison, New York
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
- Interventions
- LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Device · Drug
- Lead sponsor
- Brian O'Neill MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Peripheral Arterial Disease
- Interventions
- Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
- Drug · Other
- Lead sponsor
- Leonardo Clavijo
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- NP001, Placebo
- Drug
- Lead sponsor
- Neuraltus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Head Lice, Pediculosis Capitis
- Interventions
- X92001752, RID Super Max Solution, Nix Crème, Pouxit Végétal
- Device · Drug
- Lead sponsor
- Oystershell NV
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Plantation, Florida
- Conditions
- Epilepsy With Simple or Complex Partial Onset Seizures
- Interventions
- Eslicarbazepine acetate
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis
- Interventions
- Ketamine hydrochloride injection, Placebo
- Drug · Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 24 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Brookline, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BCT197, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
- Conditions
- Pancreatic Cyst, EUS-FNA
- Interventions
- Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Hershey, Pennsylvania
- Conditions
- Mild Cognitive Impairment (MCI), Amyloid Pathology
- Interventions
- Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
- Device
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Interventions
- Intra-lymphatic allergenic extract, Intra-lymphatic placebo
- Biological
- Lead sponsor
- Christopher Thompson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Austin, Texas • Grapevine, Texas • San Antonio, Texas
- Conditions
- Digestion, Abdominal Pain, GI Disorders
- Interventions
- Radicle GI Health Placebo Control Form 1, Radicle GI Health Active Study Product 1.1 Usage, Radicle GI Health Placebo Control Form 2, Radicle GI Health Active Study Product 2.1 Usage, Radicle GI Health Active Study Product 2.2 Usage, Radicle GI Health Placebo Control Form 3, Radicle GI Health Active Study Product 3.1 Usage
- Dietary Supplement
- Lead sponsor
- Radicle Science
- Industry
- Eligibility
- 21 Years to 105 Years
- Enrollment
- 2,180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- Rosacea
- Interventions
- Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1%, Placebo Control
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Hawthorne, New York
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
- Interventions
- calcium, cholecalciferol, zoledronic acid
- Dietary Supplement · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Madison, Wisconsin
- Conditions
- Congestive Heart Failure
- Interventions
- carvedilol, placebo
- Drug
- Lead sponsor
- Shaddy, Robert, M.D.
- Individual
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Contraception
- Interventions
- Misoprostol, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Anesthesia, Propofol Adverse Reaction, Etomidate Adverse Reaction, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction
- Interventions
- Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Back Pain, Lower Back Pain, Cervical Pain
- Interventions
- Naltrexone and Clonidine Combination, placebo
- Drug
- Lead sponsor
- Annette C. Toledano MD
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)
- Interventions
- CC-97540
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide SAR439977, Placebo, Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more